RadioMedix & Curium Announce Permanent HCPCS Code for DetectnetTM (copper Cu 64 dotatate injection)
St. Louis, MO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that the Centers for Medicare & Medicaid Services (CMS) has granted Detectnet a permanent Healthcare Common Procedure Coding System (HCPCS) code – A9592 – effective April 1, 2021. The descriptor for this product specific A code will be: Copper Cu-64, dotatate, diagnostic, 1 millicurie. Beginning on April 1, 2021, this code will be available to bill claims for Medicare patients in non-hospital imaging centers and for private insurance patients in all imaging facilities. This information follows the recent news that Detectnet was granted Transitional Pass-Through Status by CMS (C9068) effective January 1, 2021. C9068 is used to bill Detectnet for Medicare patients seen in the hospital outpatient department.
“Once in effect, having both a permanent HCPCS code and Transitional Pass-Through Status will simplify the reimbursement process for all imaging centers that desire to use Detectnet,” said Curium CEO, North America, Dan Brague. “We remain focused on helping physicians and patients in the neuroendocrine community and anticipate the simplified reimbursement process may increase access to the product. We would like to thank CMS for their timely release of both codes, especially in light of the current COVID-19 pandemic.”
“The response to Detectnet from the neuroendocrine community is outstanding,” said Ebrahim Delpassand, MD, CEO of RadioMedix. “The Phase III results demonstrate the clinical sensitivity, specificity, and accuracy of Detectnet. Further, the 12.7 hour half-life of Detectnet enables it to be produced centrally and shipped to sites throughout the U.S. The HCPCS code and Transitional Pass-Through Status should now provide access to patients nationwide.”
Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.
IMPORTANT RISK INFORMATION
WARNINGS AND PRECAUTIONS
Diagnostic radiopharmaceuticals, including Detectnet, contribute to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.
Risk for Image Misinterpretation
The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors. Increased uptake might also be seen in other non-cancerous pathologic conditions that express somatostatin receptors including thyroid disease or in subacute inflammation, or might occur as a normal physiologic variant (e.g. uncinate process of the pancreas).
A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
In clinical trials, adverse reactions occurred at a rate of < 2% and included nausea, vomiting and flushing. In published trials nausea immediately after injection was observed.
Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2). Image patients just prior to dosing with somatostatin analogs. For patients on long-acting somatostatin analogs, a wash-out period of 28 days is recommended prior to imaging. For patients on short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging.
USE IN SPECIFIC POPULATIONS
All radiopharmaceuticals, including Detectnet, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation from administration of Detectnet.
Advise a lactating woman to interrupt breastfeeding for 12 hours after Detectnet administration in order to minimize radiation exposure to a breastfed infant.
The safety and effectiveness of Detectnet have not been established in pediatric patients.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
In the event of a radiation overdose, the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by reinforced hydration and frequent bladder voiding. A diuretic might also be considered.
Please see Full prescribing information by clicking here.
RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is commercializing radiopharmaceuticals for PET imaging and therapeutic (alpha and beta-labeled) radiopharmaceuticals. RadioMedix has also established contract service facilities for academic and industrial partners: Full cGMP manufacturing and analytical suites for human clinical trials, and commercial phase manufacturing of the radiopharmaceuticals, and probe development and small animal Molecular Imaging Facility for pre-clinical evaluation of radiopharmaceuticals in animal models. To learn more, visit www.radiomedix.com. For more information about this press release, please contact: firstname.lastname@example.org
Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit curiumpharma.com. For more information about this press release, please contact Janet Ryan, media contact for Curium: email@example.com.
About Neuroendocrine Tumors
Neuroendocrine tumors (NETs) are a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract, pancreas and liver, but can also occur in other tissues including lung, thymus and other uncommon sites such as cervix, heart and prostate. Most NETs strongly express somatostatin receptors (SSTRs).
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Notice of the Annual General Meeting of Nokia Corporation4.3.2021 11:00:00 CET | Press release
Nokia Corporation Stock Exchange Release March 4, 2021 at 12:00 (CET +1) Notice of the Annual General Meeting of Nokia Corporation Notice is given to the shareholders of Nokia Corporation (the "Company") of the Annual General Meeting to be held on Thursday April 8, 2021 at 3:00 p.m. in the Company’s headquarters at Karakaari 7, Espoo, Finland. Participation and exercise of shareholder rights in the Meeting is possible only by voting in advance and by submitting counterproposals and asking questions in advance in accordance with the instructions given in section C of this notice and otherwise by the Company. It is not possible for the shareholders or their proxy representatives to participate in the Meeting at the meeting venue. The Board of Directors of the Company has resolved on extraordinary measures pursuant to the legislative act concerning temporary deviations from the Companies Act (677/2020), which entered into force on October 3, 2020. In order to restrict the spread of the CO
Incap Corporation: Incap appoints new Managing Director to Incap Electronics Slovakia4.3.2021 11:00:00 CET | Press release
Incap Corporation Press release on 4 March 2021 at 12.00 p.m. EET Incap Corporation has made a new appointment to its team, promoting the current Plant Director of Incap Electronics Slovakia to the position of Managing Director. The company has decided to promote Miroslav Michalik to the position of Managing Director of Incap Slovakia. Miroslav Michalik has been employed by Incap Slovakia (previously AWS Slovakia) since 2018, working as a Plant Director at the company’s factory in Namestovo. “I am pleased to see Miroslav Michalik move into the Managing Director position of our factory in Slovakia. His previous role as plant manager proved that he’d be a great fit for leading the operations at Incap Slovakia," says Otto Pukk, President and CEO of Incap Group. Miroslav Michalik studied electronics at secondary school and went on to study production and general management at degree-level. Before joining Incap, he held several roles in companies within the electronics sector, from process
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS4.3.2021 10:10:00 CET | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-03-04Loan196Coupon1.00 %ISIN-codeSE0015244991Maturity2026-03-18 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln2,000 Volume bought, SEK mln800 Number of bids7 Number of accepted bids3 Average yield0.366 %Lowest accepted yield0.363 %Highest yield0.369 %% accepted at lowest yield 75.00 Auction date2021-03-04Loan1591Coupon0.50 %ISIN-codeSE0013882644Maturity2026-06-01 Tendered volume, SEK mln2,000 +/- 1,000 Volume offered, SEK mln6,000 Volume bought, SEK mln2,000 Number of bids9 Number of accepted bids4 Average yield0.398 %Lowest accepted yield0.396 %Highest yield0.401 %% accepted at lowest yield 66.67 Auction date2021-03-04Loan147 Coupon2.00 %ISIN-codeSE0009383664Maturity2026-06-17 Tendered volume, SEK mln700 +/- 350 Volume offered, SEK mln2,000 Volume bought, SEK mln700 Number of bids5 Number of accepted bids2 Average yield0.404 %Lowest accepted yield0.403 %Highest yield0.408 %% accepted at lowest yield 7
Feedzai’s Financial Crime Report: Fraud Attacks Skyrocketed in 20204.3.2021 10:00:00 CET | Press release
650% increase in Account Take Over scams from Q4 2020 as compared to Q1 2020 250% increase in online banking fraud attacks178% fraud rate increase for digital media70% of all fraud is driven by card not present (CNP) transactions48% drop in card present (CP) fraud attacks, though transaction volume only drops 20% SAN MATEO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Feedzai, the world’s leading cloud-based risk management platform, has announced its https://www.globenewswire.com/Tracker?data=FFIiWo0-gYSwotLVvvuUlvdIKBB7Rg7bIbdO1xZFBVimMTovP1SOswMjLkT3fgKR47FAEN5hp7geU-IeuEnIG4v-gMfZrR2BsFPviUmlbMUl-69nBc_kOf8OV0AQ-gMHfhtKW-_x7TN_jd9eLsgwbah7AItVKxsR0aTZcU2ctCw= Financial Crime Report Q1, 2021. Feedzai’s data from financial transactions across the world shows a stark difference in consumer behavior and financial crime in the Asia-Pacific (APAC) region as compared to Europe (EU) and North America (NA). A clear image appears - a hyper-digital world where east and west are in different rec
Nokia announces it will halve emissions from 2019 to 20304.3.2021 10:00:00 CET | Press release
Press Release Nokia announces it will halve emissions from 2019 to 2030 The Science Based Targets initiative (SBTi) has signed off Nokia’s new targets which fulfil its commitment to align with limiting the global temperature rise to 1.5°C. The previous targets were in line with a 2°C riseEmissions will be reduced in both Nokia products in use with customers as well as Nokia’s own operations 4 March 2021 Espoo, Finland – Nokia today announced that it will reduce emissions by 50% across both its own operations and products in use by 2030. The company’s new Science Based Targets (SBTs) fulfill its commitment to recalibrate in line with a 1.5°C global warming scenario. Nokia first committed to SBTs in 2017, initially with goals based on limiting global warming to 2°C. The company achieved 90% of its target savings within its own operations (scope 1 and 2) 11 years ahead of target and was on track to deliver its ‘scope 3’ targets for products in use with its customers. Nokia is now adopting
GOGL – Notice of Special General Meeting4.3.2021 09:22:38 CET | Press release
4 March 2021, Hamilton, Bermuda Golden Ocean Group Limited (NASDAQ and OSE: GOGL) (“Golden Ocean” or the "Company”) announces that a Special General Meeting of the Company will be held on 26 March 2021. A copy of the notice of the Special General Meeting and associated information can be found at our website www.goldenocean.bm and in the attached document. The Board of Directors Golden Ocean Group Limited This information is subject of the disclosure requirements pursuant to Euronext Oslo Rule Book II item 4.2.4. Attachment 210304 Notice 26 March21 Special General Meeting
Nexstim Receives Two NBS System Orders from Hospitals in Norway and the US4.3.2021 09:00:00 CET | Press release
Press Release, Helsinki, 4 March 2021 at 10.00 am (EET) Nexstim Receives Two NBS System Orders from Hospitals in Norway and the US Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces it has received to new NBS System orders from leading academic institutions in February. The two NBS 5 + NexSpeech Systems were ordered by top ranked hospitals in Norway and the United States. Both these systems will be used for pre-operative motor and language mapping in neurosurgery. The prominent hospital in Norway is a new customer for Nexstim. The order from the US is from an existing customer at a highly regarded academic institution. This US customer will continue to use the system clinically with the upgraded SmartFocus® TMS technology to improve outcomes for patients undergoing invasive brain surgery as well as impactful research that advances the applications in neurosurgery. Nexstim’s NBS System is the only FDA cleared system based on navigated transcranial magnetic stimulation